Salud financiera de hoja de balance de Kintor Pharmaceutical

Salud financiera controles de criterios 4/6

Kintor Pharmaceutical tiene un patrimonio de los accionistas total de CN¥391.6M y una deuda total de CN¥234.3M, lo que sitúa su ratio deuda-patrimonio en 59.8%. Sus activos y pasivos totales son CN¥739.5M y CN¥348.0M respectivamente.

Información clave

59.8%

Ratio deuda-patrimonio

CN¥234.30m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	CN¥333.77m
Patrimonio	CN¥391.58m
Total pasivo	CN¥347.97m
Activos totales	CN¥739.54m

Actualizaciones recientes sobre salud financiera

Recent updates

Is Kintor Pharmaceutical (HKG:9939) Using Debt In A Risky Way?

Oct 07

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

Nov 16

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

Apr 28

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

Dec 06

Is Kintor Pharmaceutical (HKG:9939) Using Debt Sensibly?

Sep 01

Kintor Pharmaceutical Limited (HKG:9939) Insiders Increased Their Holdings

Feb 17

What Kind Of Investors Own Most Of Kintor Pharmaceutical Limited (HKG:9939)?

Dec 23

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (CN¥371.4M) de 9939 superan a sus pasivos a corto plazo (CN¥238.3M).

Pasivo a largo plazo: Los activos a corto plazo de 9939 (CN¥371.4M) superan a sus pasivos a largo plazo (CN¥109.7M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: 9939 tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de 9939 ha crecido de 19.9% a 59.8% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: 9939 tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: 9939 tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 7.2% cada año

Salud financiera de hoja de balance de Kintor Pharmaceutical

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Is Kintor Pharmaceutical (HKG:9939) Using Debt In A Risky Way?

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

Is Kintor Pharmaceutical (HKG:9939) Using Debt Sensibly?

Recent updates

New major risk - Revenue and earnings growth

Founder recently bought HK$107k worth of stock

Kintor Pharmaceutical Limited Receives Review Approval of Incorporation for KT-939

Kintor Pharmaceutical Limited Announces Completion of First Subject Enrollment in Pivotal Clinical Trial of Kx-826 Tincture 1.0% for the Treatment of Men Adult Androgenetic Alopecia in China

Founder recently bought HK$248k worth of stock

Is Kintor Pharmaceutical (HKG:9939) Using Debt In A Risky Way?

Founder recently bought HK$249k worth of stock

Founder recently bought HK$424k worth of stock

Kintor Pharmaceutical Limited to Report First Half, 2024 Results on Aug 26, 2024

Founder recently bought HK$294k worth of stock

Kintor Pharmaceutical Limited Announces Completion of First Subject Enrollment in Phase II Clinical Trial of GT20029 Gel for Treatment of Ance in China

Kintor Pharmaceutical Limited, Annual General Meeting, Jun 20, 2024

Kintor Pharmaceutical Limited Announces Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China Reaches Primary Endpoint

Kintor Pharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

New major risk - Share price stability

Kintor Pharmaceutical Limited Announces Phase Ib/III Clinical Trial of KX-826 and Minoxidil Combination Therapy for the Treatment of Men Adults Receives Clearance by China NMPA

Founder recently bought HK$774k worth of stock

Kintor Pharmaceutical Limited Announces Results of Phase III Clinical Trial of KX-826 Topline Treatment for Men Androgenetic Alopecia

Kintor Pharmaceutical Limited Announces Results of Phase III Clinical Trial of KX-826 Topline Treatment for Men Androgenetic Alopecia

New minor risk - Share price stability

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

New major risk - Financial position

Kintor Pharmaceutical Limited Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China

Insider recently sold HK$2.6m worth of stock

Insider recently sold HK$42m worth of stock

New major risk - Revenue and earnings growth

Kintor Pharma Announces Completion of Patient Enrollment in Phase Ii Clinical Trial of Gt20029 for Treatment of Androgenetic Alopecia in China

Kintor Pharmaceutical Limited to Report First Half, 2023 Results on Aug 28, 2023

Kintor Pharmaceutical Limited Announces Completion of First Patient Enrollment in Long-Term Safety Trial of Kx-826

Kintor Pharmaceutical Limited, Annual General Meeting, Jun 15, 2023

Kintor Pharmaceutical Limited Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US

Kintor Pharmaceutical Limited Announces Successful Completion of Phase I Clinical Trial of GT1708F for Treatment of Hematological Malignancies in China

Insider recently sold HK$12m worth of stock

Forecast to breakeven in 2023

Kintor Pharmaceutical Limited Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World's First Topical Use PROTAC Compound

Kintor Pharmaceutical Limited has completed a Follow-on Equity Offering in the amount of HKD 517.6 million.

Kintor Pharmaceutical Limited Announces the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met

Kintor Pharmaceutical Limited Announces Top-Line Results of Phase I Clinical Trial of Gt20029 in China

Less than half of directors are independent

Kintor Pharmaceutical Limited Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of Gt20029 in the U.S

Kintor Pharmaceutical Limited Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX 826 for Acne Vulgaris in China

Kintor Pharmaceutical Limited Announces Publication of Phase Ib Data from Pruxelutamide for Ar+ Mbc in Ejc

Consensus revenue estimates fall by 98%

Kintor Pharmaceutical Limited to Report First Half, 2022 Results on Aug 29, 2022

Kintor Pharmaceutical Limited Completes Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China

Kintor Pharmaceutical Limited Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the Us

Key Executive recently sold HK$5.7m worth of stock

Kintor Pharmaceutical Limited, Annual General Meeting, Jun 30, 2022

Insider recently sold HK$60m worth of stock

Kintor Pharmaceutical Limited Announces Board Changes

Kintor Pharmaceutical Limited Announces First Patient Dosing in Multi-Regional Global Phase II Clinical Trial of ALK-1 Antibody and Nivolumab Combination Therapy for the Treatment of Advanced Hepatocellular Carcinoma

Forecast breakeven date pushed back to 2023

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

Less than half of directors are independent

Kintor Pharmaceutical Limited Announces Top-Line Results of the Phase III MRCT of Proxalutamide in Outpatients with Mild to Moderate Covid-19

Forecast breakeven date pushed back to 2023

Kintor Pharmaceutical Limited Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Aga in Female Patients

Kintor Pharma Limited Announces First Patient Dosing in Phase II Clinical Trial of KX-826 for Treatment of Androgenic Alopecia Patients in the US

Kintor Pharmaceutical Limited Announces Executive Changes

Kintor Pharma Announces First Patient Dosing in China in Phase III Clinical Trial of Proxalutamide for the Treatment of COVID-19 Outpatients

Kintor Pharmaceutical Limited Announces Dosing of First Subject in US Phase I Clinical Trial of GT20029 for Androgenic Alopecia and Acne

Kintor Pharma Announces Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826

Kintor Pharmaceutical Limited Announces First Patient Dosing of Phase III Clinical Trial of KX-826 (Pyrilutamide) for Treating Androgenic Alopecia Patients in China

Kintor Pharmaceutical Limited Provides Update Interim Analysis for Phase III Study of Proxalutamide for Patients with Mild to Moderate Covid-19 Symptoms

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

Deputy GM & Joint Company Secretary Jie Chen has left the company

Non-Executive Director Wei Zhang has left the company

Kintor Pharmaceutical Limited Receives IND Clearance by NMPA for KX-826

Kintor Pharmaceutical Limited Announces the Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized Covid-19 Patients

Non-Executive Director recently bought HK$4.3m worth of stock